Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Innovent Biologics ( (HK:1801) ) has shared an announcement.
Innovent Biologics, Inc. has announced that its Board of Directors will hold a meeting on August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on the development, manufacturing, and commercialization of biologic drugs for the treatment of cancer, autoimmune, and other major diseases. It is listed on the Stock Exchange of Hong Kong and operates within the healthcare industry.
YTD Price Performance: 154.10%
Average Trading Volume: 24,217,049
Technical Sentiment Signal: Buy
Current Market Cap: HK$159B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.